{"entity":{"id":"celldex","kind":"company","name":"Celldex Therapeutics","aka":[],"tldr":"Biotech that ran one of the early GPNMB ADCs in triple-negative breast cancer, which failed, and has since pivoted to mast-cell (KIT) antibodies for allergic disease.","summary":"Glembatumumab vedotin (CDX-011, GPNMB-directed MMAE ADC) did not meet its primary endpoint in the METRIC trial in GPNMB-overexpressing metastatic TNBC (2018). Celldex's lead asset is now barzolvolimab, an anti-KIT antibody in phase 3 for chronic urticaria; its oncology footprint is historical but instructive for ADC target selection.","asOf":"2026-09-04","links":[{"label":"Celldex pipeline","url":"https://celldex.com/pipeline/"}],"tags":["failure","adc-history"],"related":[],"cancers":["tnbc"],"sections":["adcs","immunotherapy"],"technologies":["adc"],"targets":["kit"],"drugs":["rindopepimut"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Hampton, NJ","country":"US","companyType":"biotech","website":"https://www.celldex.com","ticker":"CLDX","investors":[],"funding":[]},"route":"/companies/celldex/","neighbours":{"cancer":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"target":[{"id":"kit","kind":"target","name":"KIT","route":"/targets/kit/"}],"drug":[{"id":"rindopepimut","kind":"drug","name":"Rindopepimut","route":"/drugs/rindopepimut/"}],"trial":[{"id":"act-iv","kind":"trial","name":"ACT IV","route":"/trials/act-iv/"}]}}